Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QTX-2101 + all-trans retinoic acid
- Development stage
- Phase 4
- Lead developer
- Quetzal Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
QTX-2101 + all-trans retinoic acid (ATRA) is an investigational combination therapy being developed by Quetzal Therapeutics for the treatment of newly diagnosed low- or intermediate-risk acute promyelocytic leukemia (APL). QTX-2101 is an oral capsule formulation of arsenic trioxide (ATO), designed to provide a more convenient alternative to the standard-of-care intravenous ATO (Trisenox). The mechanism of action involves a synergistic approach: arsenic trioxide induces the degradation of the PML-RARA fusion protein, the primary driver of APL, while ATRA (tretinoin) acts as a differentiating agent that promotes the maturation of promyelocytes into mature granulocytes. This combination aims to maintain the high efficacy of the ATO-ATRA regimen while significantly reducing the treatment burden associated with frequent clinic visits and lengthy intravenous infusions. The therapy is currently being evaluated in a global Phase III clinical trial and has received FDA Fast Track designation.
- Other names
- QTX-2101 + ATRAoral arsenic trioxide + all-trans retinoic acidoral arsenic trioxide + ATRAoral arsenic trioxide + tretinoin
02
Targets
PML-RARA (PML-retinoic acid receptor alpha fusion protein)RARA (Retinoic acid receptor alpha)
Beyond the preview
Go deeper on QTX-2101 + all-trans retinoic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QTX-2101 + all-trans retinoic acid.